As a result, tumors are able to evade immune surveillance [13].Notably, recent numerous studies have shown that the PD-1/PD-L1 signaling pathway is intimately linked to tumorigenesis and progression, and blocking this pathway has emerged as a promising target for cancer immunotherapy [14–16]. The gene discussed is CD274; the disease is cancer.